Loading...

Brilliant Violet 421™ anti-mouse CD19 Antibody

Pricing & Availability
Clone
6D5 (See other available formats)
Regulatory Status
RUO
Other Names
B4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1-6D5_BV421_032911
C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 1-6D5_BV421_032911
    C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 2-6D5_BV421_CD19_Antibody_2_041619
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS plus 5% rat serum for 1 hour at room temperature. Then the section was stained with 2.5 µg/ml of CD19 (clone 6D5) Brilliant Violet 421TM, 2.5 µg/ml of CD3 (clone 17A2) Alexa Fluor® 594 (red) and 2.5 µg/ml of CD11b (clone M1/70) Alexa Fluor® 488 (green) overnight at 4°C. The image was captured by 10X objective.
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
115537 125 µL 132€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
115549 50 µg 203€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
115538 500 µL 300€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CD19-expressing K562 human erythroleukemia cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemistry on Frozen tissue using the µg size, a concentration range of 1.0 - 5.0 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence7.

Application References
  1. Shoham T, et al. 2003. J. Immunol. 171:4062. (FC)
  2. Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC)
  3. Kamimura D, et al. 2006. J. Immunol. 177:306. (FC)
  4. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC)
  5. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  6. Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC)
  7. Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed
  8. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  9. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  10. Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed
  11. Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed
  12. Olive V, et al. 2013. Elife. 2:822. PubMed
  13. Miyai T, et al. 2014. PNAS. 111:11780. PubMed
Product Citations
  1. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  2. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  3. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  4. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  5. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  6. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  7. Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
  8. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  9. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  10. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  11. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  12. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  13. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  14. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
  15. Zheng Z, et al. 2020. Cell Reports. 31(13):107819. PubMed
  16. Sangesland M, et al. 2020. Immunity. 51(4):735-749. PubMed
  17. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  18. Rosalia R, et al. 2013. Immunobiology. 218:851. PubMed
  19. Weber G, et al. 2014. J Exp Med. 211:1243. PubMed
  20. Prooyen N, et al. 2016. PLoS One. 12: 1005749. PubMed
  21. Kleiman E, et al. 2016. Proc Natl Acad Sci U S A. 113: E3911 - E3920. PubMed
  22. Dibra D, et al. 2016. Clin Cancer Res. 22: 3876 - 3883. PubMed
  23. Schaum N, et al. 2020. Nature. 583:596. PubMed
  24. Kerkhofs D, et al. 2020. Theranostics. 7.022222222. PubMed
  25. Xu G, et al. 2020. Cell Rep. 32:108170. PubMed
  26. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  27. Wang Y, et al. 2020. Immunity. 53(6):1151-1167.e6. PubMed
  28. Yilmaz B, et al. 2021. Cell Host Microbe. 29(4):650-663.e9. PubMed
  29. Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed
  30. Giampazolias E, et al. 2021. Cell. . PubMed
  31. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
  32. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  33. Akoolo L, et al. 2021. Cell Microbiol. 23:e13350. PubMed
  34. Monzon-Casanova E, et al. 2021. Eur J Immunol. 51:2266. PubMed
  35. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  36. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
  37. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
  38. Steinmetz TD, et al. 2021. Autophagy. 17:2238. PubMed
  39. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  40. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  41. Bello A, et al. 2021. Immunol Cell Biol. 99:879. PubMed
  42. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  43. Jolly A, et al. 2022. Cell Rep Methods. 2:100315. PubMed
  44. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  45. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  46. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  47. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  48. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  49. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  50. Caradonna TM, et al. 2022. Cell Rep. 41:111628. PubMed
  51. Yazicioglu YF, et al. 2023. Nat Immunol. 24:991. PubMed
  52. Doloff JC, et al. 2023. Sci Adv. 9:eade9488. PubMed
RRID
AB_10895761 (BioLegend Cat. No. 115537)
AB_2563066 (BioLegend Cat. No. 115549)
AB_11203527 (BioLegend Cat. No. 115538)

Antigen Details

Structure
Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution

Pro-B cells to mature B cells (during development), follicular dendritic cells

Function
Modulates B cell activation and differentiation
Ligand/Receptor
CD21, CD81, Leu-13
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341.
2. Krop I, et al. 1996. Eur. J. Immunol. 26:238.
3. Krop I, et al. 1996. J. Immunol. 157:48.
4. Tedder TF, et al. 1994. Immunol. Today 15:437.

Gene ID
12478 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 3    Revision Date: 04.16.2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account